Genes Shape GLP1 Drug Response Weight Loss and Side Effects Explained
New research shows genetic differences may influence how patients respond to GLP1 medications like semaglutide and tirzepatide
A large genetic study suggests that individual DNA differences may partly explain why some people lose more weight or experience more side effects on GLP1 drugs, opening the door to more personalized obesity treatment.
Study Details
GLP1 receptor agonists such as semaglutide and tirzepatide have become widely used for obesity and type 2 diabetes, but pati…
Keep reading with a 7-day free trial
Subscribe to Just Healthcare to keep reading this post and get 7 days of free access to the full post archives.